Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Venous Thromboembolism 1Thrombosis 1Thrombophilia 1Thromboembolism 1Small Cell Lung Carcinoma 1Sarcoma 1Pulmonary Embolism 1Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery 1Multiple Myeloma 1Lymphoma 1Leukemia 1Hematologic Neoplasms 1Esophageal Neoplasms 1Digestive System Diseases 1

Interventions

Cisplatin 161Fluorouracil 135Paclitaxel 127Radiotherapy 125Oxaliplatin 88Carboplatin 72Docetaxel 71Irinotecan 60pembrolizumab 57Leucovorin 57Capecitabine 57Radiation 48Esophagectomy 44Surgical Procedures, Operative 41Drug Therapy 38Neoadjuvant Therapy 28Cetuximab 25Nivolumab 24Bevacizumab 21camrelizumab 20Trastuzumab 20S 1 (combination) 19Chemoradiotherapy 19Magnetic Resonance Spectroscopy 18Epirubicin 16Albumin-Bound Paclitaxel 16Blood Specimen Collection 15tislelizumab 14Taxes 14Radiotherapy, Intensity-Modulated 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Esophageal Neoplasms × enoxaparin sodium × Clear all
NCT03254511 2017-08-22

Addition of Enoxaparin to Neoadjuvant Chemoradiation of Esophageal Cancer

Mashhad University of Medical Sciences

Phase 2 Unknown
100 enrolled
Gastrointestinal

Esophageal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡